Good evening :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Pfizer Ltd

PFIZER

Pfizer Ltd

PFIZER
Health CarePharmaceuticals
SmallcapWith a market cap of ₹23,772 cr, stock is ranked 307
Low RiskStock is 1.91x as volatile as Nifty
5,097.551.90% (-98.85)
5,097.551.90% (-98.85)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹23,772 cr, stock is ranked 307
Low RiskStock is 1.91x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹23,772 cr, stock is ranked 307
Low RiskStock is 1.91x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
38.476.610.67%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.666.470.51%

Forecast & Ratings

Detailed Forecast 
67%
Analysts have suggested that investors can buy this stock

from 3 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Pfizer Limited is a pharmaceutical company. The Company has a portfolio of approximately 140 products across over 15 therapeutic areas.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

2023
Current
₹5,097.55
Baseline
Forecast for Oct 2025
High
₹—
Median
₹—
Low
₹—

All values in ₹

Loading...
2023
Current
₹5,097.55
Baseline
Forecast for Oct 2025
High
₹—
Median
₹—
Low
₹—

All values in ₹

Revenue Forecast

2024
Current
₹2.38
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—

All values in ₹ Thousand cr.

Loading...
2024
Current
₹2.38
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—

All values in ₹ Thousand cr.

Earnings Per Share Forecast

2024
Current
₹120.50
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—

All values in ₹

Loading...
2024
Current
₹120.50
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—

All values in ₹

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 1.15%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 1.02% to 0.63%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 5.14%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue2,109.222,197.852,082.802,248.892,335.672,319.672,673.642,558.812,381.632,441.89
Raw Materialssubtract735.20812.24712.17838.78829.02783.391,020.93817.19804.391,529.33
Power & Fuel Costsubtract10.4310.3412.3411.4511.045.795.676.513.98
Employee Costsubtract277.34303.89314.29323.84364.51361.06403.67331.68347.80
Selling & Administrative Expensessubtract375.97383.12316.73335.32319.66268.67310.77298.03317.96
Operating & Other expensessubtract180.53106.54112.346.4854.70107.2434.01162.4083.72
Depreciation/Amortizationsubtract57.9362.9366.2571.39103.24109.41115.00105.5162.2860.89
Interest & Other Itemssubtract1.401.960.771.7211.0115.3910.7013.4815.4314.02
Taxes & Other Itemssubtract165.44180.05187.84230.86133.36171.11160.33200.08194.74219.75
EPS66.6673.6178.7093.78111.28108.76133.88136.37120.50135.05
DPS15.0020.0020.0022.50330.0035.0035.0070.0035.0035.00
Payout ratio0.230.270.250.242.970.320.260.510.290.26
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Pfizer Ltd43.126.610.67%
Sun Pharmaceutical Industries Ltd46.896.690.72%
Cipla Ltd28.954.450.88%
Torrent Pharmaceuticals Ltd65.7015.870.87%

Price Comparison

Compare PFIZER with any stock or ETF
Compare PFIZER with any stock or ETF
PFIZER
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding63.92%10.43%5.60%3.54%16.50%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep2.81%2.82%3.03%3.33%3.22%3.54%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 2.11%

Top 5 Mutual Funds holding Pfizer Ltd

Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Nippon India Small Cap Fund - Growth - Direct Plan

Growth
2.4130%0.94%0.12%17/238 (+104)
Quant Small Cap Fund - Growth - Direct Plan

Growth
1.8179%1.62%1.58%69/110 (+27)
SBI Innovative Opportunities Fund - Direct Plan - Growth

Growth
0.9256%2.69%2.69%15/38 (-5)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.67%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.74 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 21, 2024

Final
Final | Div/Share: ₹35.00

Dividend/Share

₹35.00

Ex DateEx Date

Aug 21, 2024

Cash Dividend

Ex DateEx DateAug 11, 2023

Final
Final | Div/Share: ₹35.00

Dividend/Share

₹35.00

Ex DateEx Date

Aug 11, 2023

Cash Dividend

Ex DateEx DateAug 11, 2023

Special
Special | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Aug 11, 2023

Cash Dividend

Ex DateEx DateSep 19, 2022

Special
Special | Div/Share: ₹30.00

Dividend/Share

₹30.00

Ex DateEx Date

Sep 19, 2022

Cash Dividend

Ex DateEx DateAug 18, 2022

Final
Final | Div/Share: ₹35.00

Dividend/Share

₹35.00

Ex DateEx Date

Aug 18, 2022

News & Opinions
Earnings
Pfizer standalone net profit rises 6.30% in the September 2024 quarter

Net profit of Pfizer rose 6.30% to Rs 158.35 crore in the quarter ended September 2024 as against Rs 148.96 crore during the previous quarter ended September 2023. Sales rose 2.33% to Rs 588.59 crore in the quarter ended September 2024 as against Rs 575.21 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales588.59575.21 2 OPM %32.1531.75 - PBDT230.22215.95 7 PBT215.23200.52 7 NP158.35148.96 6 Powered by Capital Market - Live

1 day agoCapital Market - Live
Corporate
Pfizer announces board meeting date

Pfizer will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Pfizer to hold AGM

Pfizer announced that the Annual General Meeting (AGM) of the company will be held on 28 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Pfizer raises annual profit forecast on strong sales of cancer, heart drugs

3 months agoBusiness Standard
Anil Singhvi Stock of the day | Buy Pfizer & ITD Cementation
3 months agoZee Business
Stock of the day | Anil Singhvi ने दी Pfizer & ITD Cementation में खरीदारी की राय..
3 months agoZee Business

Pfizer standalone net profit rises 61.14% in the June 2024 quarter

3 months agoBusiness Standard

Pfizer Q1 Results Review - On A Recovery Path, Growth Should Strengthen: Systematix

3 months agoBloomberg Quint
Earnings
Pfizer standalone net profit rises 61.14% in the June 2024 quarter

Net profit of Pfizer rose 61.14% to Rs 150.71 crore in the quarter ended June 2024 as against Rs 93.53 crore during the previous quarter ended June 2023. Sales rose 5.93% to Rs 562.86 crore in the quarter ended June 2024 as against Rs 531.36 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales562.86531.36 6 OPM %31.5320.84 - PBDT217.22141.30 54 PBT202.62125.75 61 NP150.7193.53 61 Powered by Capital Market - Live

3 months agoCapital Market - Live
June Quarter Earnings Report: HPCL, ACC, Colgate-Palmolive, Pfizer—Which Stocks Are in Focus?
3 months agoZee Business